Patients in the SCULPTURE extension received the same blinded maintenance treatment regimen and dose up to the end of Year 3; the study became open label in Year 4. For patients who were administered Cosentyx 300mg every 4 weeks, almost clear skin (PASI 90) was achieved by 68.5% of patients at Year 1, 61.9% of patients at Year 3, and maintained at Year 4 in 66.4% of patients.
Completely clear skin (PASI 100) was achieved by 43.8% of patients at Year 1, 41.7% of patients at Year 3, and maintained at Year 4 in 43.5% of patients. PASI 75 skin clearance, the historic standard treatment goal, was achieved by 88.9% of patients at Year 1, 78.4% of patients at Year 3, and maintained at 88.5% of patients at Year 4.
In addition, data from the GESTURE study showed that 40% of patients treated with Cosentyx 300mg every 4 weeks achieved clear or almost clear palms and soles at Week 16; at Week 80, about 60% of patients achieved clear or almost clear palms and soles.
Cosentyx is a human monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine. It works by inhibiting its interaction with the IL-17 receptor. In addition to its use in psoriasis, Cosentyx is also indicated for adult patients with active ankylosing spondylitis and active psoriatic arthritis.
For more information call (888) 669-6682 or visit Cosentyx.com.